News
Better Buy: Ziopharm Oncology Inc. vs. Celldex Therapeutics, Inc.
The American Cancer Society expects 600,920 Americans to die from cancer this year, but Ziopharm Oncology Inc. (NASDAQ: ZIOP) and Celldex Therapeutics, Inc. (NASDAQ: CLDX) aim to lower that....
Here's Where Things Went Wrong for Celldex Therapeutics, Inc. in 2017
For Celldex Therapeutics (NASDAQ: CLDX), 2016 was a horrible year. The biotech stock dropped 77% after experimental vaccine Rintega flopped in a late-stage clinical study. Celldex entered 2017....
Here's What's Behind Synergy Pharmaceuticals' 15.6% Drop Today
After pricing an equity offering that will dilute current investors but help shore up its balance sheet, shares in Synergy Pharmaceuticals (NASDAQ: SGYP) are tumbling 15.6% as of 1:45 p.m.....
Here's Why Teligent Stock Was Cut Nearly in Half Today
Shares of specialty generic pharmaceutical manufacturer Teligent (NASDAQ: TLGT) dropped as much as 46% today after investors digested the company's third-quarter 2017 results. Operations appeared....
Why Celldex Therapeutics Jumped Higher Today
Celldex Therapeutics, Inc. (NASDAQ: CLDX) is up 16% at 12:04 p.m. EST after releasing third-quarter earnings this morning, although the stock move likely has more to do with data released in....
Celldex Therapeutics, Inc.'s Most Important Takeaway From Q3 Isn't a Number
Investors view quarterly updates from clinical-stage biotechs in a very different way than they do for other companies. The bottom line isn't nearly as important for these small biotechs as are....
Why Celldex Therapeutics Stock Crumbled in October
Shares of the clinical-stage biotech Celldex Therapeutics (NASDAQ: CLDX) fell by 14.7% in October, according to S&P Global Market Intelligence. The good news -- if you can call it that -- is....
Why This Marijuana Stock Imploded 42% in October
Medical marijuana upstart Insys Therapeutics (NASDAQ: INSY) had a ferociously frightening month, highlighted by the arrest of its founder, the setting aside of $150 million for lawsuits, and....
Why This Marijuana Stock Didn't Sink Despite a Huge Earnings Miss
Wall Street analysts expected Insys Therapeutics (NASDAQ: INSY) to report dismal third-quarter results. But they didn't know just how bad those results would actually be.Insys announced its....
Up in Smoke: This Marijuana Stock Imploded Last Week
Few industries have put a wider smile on investors' faces this year than marijuana. As recently as June, the average marijuana stock was higher by more than 330% over the trailing 12-month period,....
3 Small-Cap Marijuana Stocks to Get on Your Radar
When it comes to the fastest-growing, and riskiest, industries in the stock market, none takes the cake like legal marijuana.According to cannabis research firm The Arcview Group, legal sales in....
ALPHA MOS : CHIFFRE D'AFFAIRES NEUF MOIS 2017
En M€ - Normes IFRS
Données non auditées
2017
2016
Variation
Chiffre d'affaires 1er semestre
2,1
3,9
-47%
Chiffre d'affaires 3ème....
The Double Whammy That Sent Marijuana Stock Insys Therapeutics Crashing as Much as 30%
Shares of Insys Therapeutics (NASDAQ: INSY), a small-cap biotech with a focus on pain management, plunged as much as 30% on Wednesday after receiving a double whammy. One whammy was the arrest of....
Why DBV Technologies SA Plummeted and Aimmune Therapeutics Inc Skyrocketed Today
DBV Technologies (NASDAQ: DBVT) is down 45% at 12:48 p.m. EDT after announcing that its peanut allergy treatment, Viaskin Peanut, failed -- albeit not by much -- a phase 3 trial. The results....
This Marijuana Stock Could Be the Biggest Comeback Story of 2018
Insys Therapeutics (NASDAQ: INSY) is one of the most hated biotech stocks on the market today. That's the case, at least, if you use short interest as a proxy for how much investors hate a given....
Legalizing Recreational Marijuana in Colorado Reversed a 14-Year Trend of Rising Opioid-Related Deaths
The marijuana industry is, for lack of a better pun, sprouting like a weed. According to cannabis research firm ArcView, the North American legal weed market grew by 34% in 2016 and is expected to....
10 Stunning Numbers You Need to Know About Breast Cancer
October is breast cancer awareness month. Of course, for many American families, there's no need for a month to be designated to remember breast cancer. They're more than aware of the disease....
The Most Disappointing Marijuana Stock Plunged Once Again Last Week
The legal-marijuana industry is growing at an incredible pace, which is a big reason why investors seemingly can't get enough of pot stocks. According to Marijuana Business Daily's latest report,....
ALPHA MOS : INFORMATIONS RELATIVES AU NOMBRE TOTAL DE DROITS DE VOTE ET D'ACTIONS
INFORMATIONS RELATIVES AU NOMBRE TOTAL DE DROITS DE VOTE ET D'ACTIONS PREVUES PAR L'ARTICLE L. 233-8 II DU CODE DE COMMERCE ET L'ARTICLE 223-16 DU REGLEMENT GENERAL DE L'AUTORITE DES MARCHES....
After Gaining 16% Early Last Week, This Marijuana Stock Quickly Kissed It All Goodbye
Few industries, if any, offer the type of growth that legal cannabis can bring to the table, which is a big reason why investors have flocked to marijuana stocks in droves. Many of the largest pot....
This Company Gained 76% in its IPO -- and It Isn't Even a Tech Company
In a sure sign that the biotech bull market is alive and well, Rhythm Pharmaceuticals (NASDAQ: RYTM) raised almost $120 million at $17 per share in its initial public offering on Thursday. In its....
What's Behind Celldex Therapeutics, Inc.'s 16% Rally in September?
Shares of Celldex Therapeutics, Inc. (NASDAQ: CLDX), a clinical-stage biotech, rose 16.3% in September, according to data from S&P Global Market Intelligence. It looks like investors....
This U.S. Marijuana Stock Is Arguably the Best on the Market -- and It's Dirt Cheap
What's the best U.S. marijuana stock on the market right now?Including only the U.S. in the question excludes several of the top candidates, such as U.K.-based GW Pharmaceuticals (NASDAQ: GWPH)....
ALPHA MOS : INFORMATIONS RELATIVES AU NOMBRE TOTAL DE DROITS DE VOTE
INFORMATIONS RELATIVES AU NOMBRE TOTAL DE DROITS DE VOTE ET D'ACTIONS PREVUES PAR L'ARTICLE L. 233-8 II DU CODE DE COMMERCE ET L'ARTICLE 223-16 DU REGLEMENT GENERAL DE L'AUTORITE DES MARCHES....
Why Celldex Therapeutics, Inc. Jumped Higher Today
Celldex Therapeutics (NASDAQ: CLDX) closed on Monday up 12.8%, with no apparent news to justify the double-digit gain by the biotech company.The move follows an 8.1% jump on Friday. Sometimes,....